Hanmi Pharm Co Ltd
KRX:128940

Watchlist Manager
Hanmi Pharm Co Ltd Logo
Hanmi Pharm Co Ltd
KRX:128940
Watchlist
Price: 264 500 KRW -0.75%
Market Cap: 3.4T KRW
Have any thoughts about
Hanmi Pharm Co Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Hanmi Pharm Co Ltd stock under the Base Case scenario is 392 626.04 KRW. Compared to the current market price of 264 500 KRW, Hanmi Pharm Co Ltd is Undervalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
392 626.04 KRW
Undervaluation 33%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
96
vs Industry
45
Median 3Y
2.6
Median 5Y
2.7
Industry
2.5
Forward
2.1
More Details
20.9
P/E
P/E
Price to Earnings
20.9
vs History
88
vs Industry
20
Median 3Y
34.4
Median 5Y
40.2
Industry
21.8
Forward
19.2
More Details
15
P/OCF
P/OCF
Price to OCF
15
vs History
66
vs Industry
28
Median 3Y
15.6
Median 5Y
20.2
Industry
16.1
More Details
47.3
P/FCFE
P/FCFE
Price to FCFE
47.3
vs History
69
vs Industry
11
Median 3Y
48.7
Median 5Y
76.8
Industry
23.8
More Details
3.1
P/B
P/B
Price to Book Value
3.1
vs History
96
vs Industry
20
Median 3Y
3.9
Median 5Y
4
Industry
2.1
More Details
2.3
EV/S
EV/S
Enterprise Value to Sales
2.3
vs History
95
vs Industry
42
Median 3Y
2.8
Median 5Y
3
Industry
2.7
Forward
2.2
More Details
4.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.2
vs History
95
vs Industry
44
Median 3Y
5
Median 5Y
5.5
Industry
5.2
More Details
10.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.3
vs History
96
vs Industry
31
Median 3Y
13.5
Median 5Y
16
Industry
13.5
Forward
10.3
More Details
14.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.3
vs History
96
vs Industry
26
Median 3Y
21
Median 5Y
25.9
Industry
16.8
Forward
14.1
More Details
16.4
EV/OCF
EV/OCF
Enterprise Value to OCF
16.4
vs History
68
vs Industry
28
Median 3Y
16.7
Median 5Y
22
Industry
15.2
More Details
22
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
22
vs History
46
vs Industry
21
Median 3Y
21.4
Median 5Y
21.4
Industry
19.3
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
61
vs Industry
32
Median 3Y
2.3
Median 5Y
2.3
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Hanmi Pharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Hanmi Pharm Co Ltd
KRX:128940
3.4T KRW 2.1 20.9 10.3 14.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 18.5 90.4 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
251.6B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
199.5B CHF 3.4 17.3 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4.1 31.4 168.9 253.1
CH
Novartis AG
SIX:NOVN
171.3B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
KR
Hanmi Pharm Co Ltd
KRX:128940
Average P/S: 382 942.2
2.1
26%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
KR
Hanmi Pharm Co Ltd
KRX:128940
Average P/E: 31.1
20.9
51%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.3
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
Hanmi Pharm Co Ltd
KRX:128940
Average EV/EBITDA: 414.6
10.3
28%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
168.9
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
Hanmi Pharm Co Ltd
KRX:128940
Average EV/EBIT: 1 811.5
14.3
42%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.1
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.